<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biomed Res Int</journal-id><journal-id journal-id-type="iso-abbrev">Biomed Res Int</journal-id><journal-id journal-id-type="publisher-id">BMRI</journal-id><journal-title-group><journal-title>BioMed Research International</journal-title></journal-title-group><issn pub-type="ppub">2314-6133</issn><issn pub-type="epub">2314-6141</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26949703</article-id><article-id pub-id-type="pmc">4754465</article-id><article-id pub-id-type="doi">10.1155/2016/5985327</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Recombinant Brain Natriuretic Peptide for the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease Undergoing Nonemergent Percutaneous Coronary Intervention or Coronary Angiography: A Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Jinming</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Yanan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Fang</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Zihan</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Yuming</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zu</surname><given-names>Xiuguang</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Liang</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yongjun</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Cardiology, Second Hospital, Hebei Medical University, Shijiazhuang, Hebei 050000, China</aff><aff id="I2"><sup>2</sup>Department of Cardiology, Weixian Hospital of Traditional Chinese Medicine, Xingtai, Hebei 054700, China</aff><author-notes><corresp id="cor1">*Jinming Liu: <email>liujinming74@163.com</email></corresp><fn fn-type="other"><p>Academic Editor: Francesco Onorati</p></fn></author-notes><pub-date pub-type="ppub"><year>2016</year></pub-date><pub-date pub-type="epub"><day>2</day><month>2</month><year>2016</year></pub-date><volume>2016</volume><elocation-id>5985327</elocation-id><history><date date-type="received"><day>25</day><month>8</month><year>2015</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Jinming Liu et al.</copyright-statement><copyright-year>2016</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The role of brain natriuretic peptide (BNP) in the prevention of contrast-induced nephropathy (CIN) is unknown. This study aimed to investigate BNP's effect on CIN in chronic kidney disease (CKD) patients undergoing elective percutaneous coronary intervention (PCI) or coronary angiography (CAG). The patients were randomized to BNP (0.005&#x02009;<italic>&#x003bc;</italic>g/kg/min before contrast media (CM) exposure and saline hydration, <italic>n</italic> = 106) or saline hydration alone (<italic>n</italic> = 103). Cystatin C, serum creatinine (SCr) levels, and estimated glomerular filtration rates (eGFR) were assessed at several time points. The primary endpoint was CIN incidence; secondary endpoint included changes in cystatin C, SCr, and eGFR. CIN incidence was significantly lower in the BNP group compared to controls (6.6% versus 16.5%, <italic>P</italic> = 0.025). In addition, a more significant deterioration of eGFR, cystatin C, and SCr from 48&#x02009;h to 1 week (<italic>P</italic> &#x0003c; 0.05) was observed in controls compared to the BNP group. Although eGFR gradually deteriorated in both groups, a faster recovery was achieved in the BNP group. Multivariate logistic regression revealed that using &#x0003e;100&#x02009;mL of CM (odds ratio: 4.36, <italic>P</italic> = 0.004) and BNP administration (odds ratio: 0.21, <italic>P</italic> = 0.006) were independently associated with CIN. Combined with hydration, exogenous BNP administration before CM effectively decreases CIN incidence in CKD patients.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Contrast-induced nephropathy (CIN) is a prevalent but underdiagnosed complication of percutaneous coronary intervention (PCI) and is associated with prolonged hospitalization and high mortality [<xref rid="B1" ref-type="bibr">1</xref>]. Although the exact pathogenesis of CIN is still incompletely understood, multiple factors, including renal vasoconstriction, direct cytotoxic effects of contrast media (CM), oxidative stress, inflammation, and tubular obstruction, are likely involved [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>]. Many risk factors are associated with CIN including the preexistence of renal dysfunction, hypotension, heart failure, diabetes mellitus, older age, anemia, and CM amount and type [<xref rid="B4" ref-type="bibr">4</xref>&#x02013;<xref rid="B6" ref-type="bibr">6</xref>]. Among them, baseline renal dysfunction is arguably the most important risk factor [<xref rid="B6" ref-type="bibr">6</xref>]. Indeed, the incidence of acute renal insufficiency after PCI ranges from 2% in patients with normal baseline renal function to 20&#x02013;30% in those with baseline serum creatinine (SCr) levels &#x0003e;176&#x02009;<italic>&#x003bc;</italic>mol/L (or &#x0003e;2&#x02009;mg/dL) [<xref rid="B7" ref-type="bibr">7</xref>]. Therefore, protecting the kidneys before the use of CM is clinically relevant for patients with chronic kidney disease (CKD). Several prevention strategies have been proposed in recent years such as low dose of low osmolar or isotonic CM, hydration, and nephroprotective drugs (N-acetyl-cysteine, vasoactive drugs, and statins), but no optimal strategy for preventing CIN has yet been established.</p><p>After exposure to CM, an initial increase in blood flow occurs, followed by a sustained reduction due to a direct vasoconstrictor effect of CM, activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS), and CM-induced release of several endogenous vasoconstrictors such as adenosine and endothelin [<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B8" ref-type="bibr">8</xref>].</p><p>Brain natriuretic peptide (BNP) is a member of the natriuretic peptide family, has vasodilatory functions [<xref rid="B9" ref-type="bibr">9</xref>], and has various renoprotective effects (including renal plasma flow improvement, reduction of sodium reabsorption in the proximal tubule and collecting duct, and lowering of plasma levels of several vasoconstrictors) [<xref rid="B10" ref-type="bibr">10</xref>]. Studies have reported that low dose of atrial natriuretic peptide (the first member of the natriuretic peptide family) is beneficial in acute renal impairment after CM exposure [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Interestingly, BNP infusion not only inhibits the systemic and regional (renal and cardiac) sympathetic tones [<xref rid="B13" ref-type="bibr">13</xref>] as well as the RAAS [<xref rid="B14" ref-type="bibr">14</xref>], but also decreases endothelin release [<xref rid="B15" ref-type="bibr">15</xref>]. Furthermore, BNP has multiple beneficial effects on renal function [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>]. With respect to vasodilatation, BNP may increase renal blood flow and glomerular filtration rate [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>Despite the large body of evidence regarding the beneficial effects of BNP, studies assessing this natriuretic peptide for its preventive role in CIN are scarce. Therefore, the present study aimed to determine whether low-dose BNP has a prophylactic effect against CIN in patients with CKD undergoing PCI or coronary angiography (CAG). We found that exogenous BNP administration before CM exposure significantly decreases CIN incidence in patients with CKD.</p></sec><sec id="sec2"><title>2. Patients and Methods</title><sec id="sec2.1"><title>2.1. Study Design</title><p>This study was approved by the Ethics Committee of the Second Hospital of Hebei Medical University. All patients provided a written informed consent before enrolment. This was a randomized, open-label, control trial of rhBNP versus vehicle control. Patients were randomly assigned to one of the two groups in a 1&#x02009;:&#x02009;1 ratio in permuted blocks of four.</p></sec><sec id="sec2.2"><title>2.2. Patients</title><p>Consecutive eligible patients with CKD aged between 18 and 80 years undergoing CAG or elective PCI from October 2011 to October 2013 at the Second Hospital of Hebei Medical University were enrolled. CKD was defined as baseline estimated glomerular filtration rate (eGFR) between 15 and 60&#x02009;mL/min/1.73&#x02009;m<sup>2</sup> as assessed by the simplified Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186.3 (SCr)<sup>&#x02212;1.154</sup> (age)<sup>&#x02212;0.203</sup> (female: &#x000d7;0.742) [<xref rid="B20" ref-type="bibr">20</xref>]. Patients with acute myocardial infarction (AMI) (ST segment as well as non-ST segment elevation MI) who needed emergency PCI were excluded. In addition, individuals with unstable angina who needed early invasive therapy (within 12&#x02013;24&#x02009;h) were not enrolled; they comprised patients with (1) refractory angina, or hemodynamic or electrical instability, (2) elevated risk of clinical events (heart failure/serious ventricular arrhythmias), and (3) high-risk (resting angina within 48&#x02009;h or infarction angina, ST segment depression more than 1&#x02009;mm and 20&#x02009;min, and elevated cardiac biomarkers such as troponin [Tn] T and TnI). Other exclusion criteria were as follows: heart dysfunction (symptoms of dyspnea, orthopnea, or paroxysmal nocturnal dyspnea, accompanied by a left ventricular ejection fraction &#x0003c;40%); hypersensitivity to CM or BNP; end-stage renal failure; systolic blood pressure &#x02264;100&#x02009;mmHg before study drug infusion; CM administered within the past 7 days; BNP infusion within 1 month; administration of dopamine, N-acetyl-cysteine, sodium bicarbonate, and fenoldopam during the study.</p><p>Clinical data of all enrolled patients were obtained, including demographic data, medical history, laboratory results, medications, the extent of coronary artery lesions, and CM amount and type. Adverse events occurring during hospitalization and during the month after hospitalization were recorded. Hypotension was defined as systolic pressure &#x0003c;90&#x02009;mmHg.</p></sec><sec id="sec2.3"><title>2.3. Procedure</title><p>Patients were randomized to the control (<italic>n</italic> = 103) or BNP (<italic>n</italic> = 106) groups. Patients in the BNP group received 0.005&#x02009;<italic>&#x003bc;</italic>g/kg/min of rhBNP (Lyophilized Recombinant Human Brain Natriuretic Peptide, Chengdu Nuodikang Biological Pharmaceutical Co. Ltd., China) for 24&#x02009;h before the procedure (CAG or PCI) and hydration (0.9% NaCl at 1.0&#x02009;mL/kg/h for 12&#x02009;h before and 12&#x02009;h after CM administration). Controls received hydration only. Randomization was performed at a 1&#x02009;:&#x02009;1 ratio with a computer-generated random number table. Visipaque (Iodixanol Injection, GE Healthcare, Ireland), a nonionic, isotonic CM, was used in all patients.</p><p>The primary endpoint was the incidence of CIN, which was defined as a relative (&#x02265;25%) or absolute (&#x02265;0.5&#x02009;mg/dL, 44&#x02009;<italic>&#x003bc;</italic>mol/L) increase in SCr from baseline within 48&#x02009;h after CM exposure. The secondary endpoints were the changes in SCr, eGFR, and serum cystatin C levels before and after the procedure. Cystatin C levels, SCr levels, and eGFR were assessed before and at 24&#x02009;h, 48&#x02009;h, 1 week, and 1 month after the procedure (CAG or PCI).</p></sec><sec id="sec2.4"><title>2.4. Detection of SCr Levels</title><p>Blood samples (3&#x02009;mL) were collected in tubes containing an anticoagulant 24&#x02009;h before angiography and BNP infusion and at 24&#x02009;h, 72&#x02009;h, 1 week, and 1 month after CM exposure. Patients were required to fast overnight before blood collection in the morning. Blood samples were centrifuged at 800&#x02009;rpm and room temperature (20&#x02013;25&#x000b0;C) for 10&#x02009;min to obtain serum. SCr levels were determined by the picric acid method. Cystatin C levels were assessed by immunonephelometry on a Roche 8000 autoanalyzer (Roche, Switzerland).</p></sec><sec id="sec2.5"><title>2.5. Statistical Analysis</title><p>Sample size (<italic>n</italic>) was determined by the equation <italic>n</italic> = (<italic>Z</italic>
<sub>1</sub> &#x02212; <italic>&#x003b1;</italic>/2 + <italic>Z</italic>
<sub>1</sub> &#x02212; <italic>&#x003b2;</italic>)2 &#x000d7; [<italic>P</italic>
<sub>1</sub>(1 &#x02212; <italic>P</italic>
<sub>1</sub>) + <italic>P</italic>
<sub>2</sub>(1 &#x02212; <italic>P</italic>
<sub>2</sub>)]/(<italic>P</italic>
<sub>1</sub> &#x02212; <italic>P</italic>
<sub>2</sub>)2, with <italic>&#x003b1;</italic> = 0.05; <italic>&#x003b2;</italic> = 0.1; <italic>P</italic>
<sub>1</sub> = 16%, CIN incidence in the control group; <italic>P</italic>
<sub>2</sub> = 6%, CIN incidence in the BNP group. The modified intention-to-treat population was analyzed. All statistical analyses were performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Data are presented as mean &#x000b1; standard deviation (SD) or median (interquartile ranges) for continuous variables and proportions for categorical variables. The independent samples <italic>t</italic>-test was used to compare continuous variables and the <italic>&#x003c7;</italic>
<sup>2</sup>-test or Fisher's exact test for categorical variables. Repeated measure ANOVA and the Bonferroni post hoc test were used to evaluate the changes in variables within the same group. Multivariate logistic regression analysis was used to identify independent predictors of CIN. Two-sided <italic>P</italic> values &#x0003c;0.05 were considered statistically significant.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec id="sec3.1"><title>3.1. Characteristics of the Patients</title><p>A total of 222 patients were initially eligible for this study. Four declined to participate. Of the 218 randomized patients (BNP group, <italic>n</italic> = 109; control group, <italic>n</italic> = 109), 209 completed the study. Before starting the trial, one patient suffered from hypotension; two patients had heart dysfunction (symptoms of dyspnea, orthopnea, or paroxysmal nocturnal dyspnea, accompanied by a left ventricular ejection fraction &#x0003c;40%); one patient suffered from refractory angina and needed early invasive therapy before the study; one patient had end-stage renal failure; and four patients were lost to follow-up after the procedure. Finally, 106 and 103 patients were analyzed in the BNP and control groups, respectively (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>The 209 patients included 133 men and 76 women, aged 68.7 &#x000b1; 8.9 years; no significant differences between the two groups were observed for demographic data, medical history, laboratory test, medications, the extent of coronary artery lesions, and CM amount (<xref ref-type="table" rid="tab1">Table 1</xref>).</p></sec><sec id="sec3.2"><title>3.2. Incidence of CIN</title><p>A lower incidence of CIN was found in patients treated with rhBNP compared to controls. Indeed, the incidence of a SCr increase of &#x02265;25% or &#x02265;0.5&#x02009;mg/dL from baseline was significantly lower in the BNP group compared to controls (6.6% versus 16.5%, <italic>P</italic> = 0.025). The incidence rates of a SCr increase of &#x02265;0.5&#x02009;mg/dL were 3.8% and 13.6% in BNP-treated patients and controls, respectively (<italic>P</italic> = 0.011). When defined as a SCr increase of &#x02265;25%, the incidence of CIN was also lower in the BNP group compared to the control group (5.7% versus 16.5%, <italic>P</italic> = 0.012) (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p></sec><sec id="sec3.3"><title>3.3. Effects of rhBNP on Renal Function</title><p>As shown in <xref ref-type="table" rid="tab2">Table 2</xref>, baseline cystatin C (1.14 &#x000b1; 0.22 versus 1.17 &#x000b1; 0.36, <italic>P</italic> = 0.251), SCr (117.2 &#x000b1; 13.1 versus 120.5 &#x000b1; 14.7, <italic>P</italic> = 0.33), and eGFR (52.3 &#x000b1; 11.2 versus 50.9 &#x000b1; 9.3, <italic>P</italic> = 0.293) were similar between the two groups. Nevertheless, a more significant deterioration was observed in the control group compared to BNP-treated patients. Cystatin C levels for the control and BNP groups were 1.56 &#x000b1; 0.29&#x02009;mg/L and 1.75 &#x000b1; 0.94&#x02009;mg/L (48&#x02009;h, <italic>P</italic> = 0.027) and 1.20 &#x000b1; 0.24&#x02009;mg/L and 1.88 &#x000b1; 0.82&#x02009;mg/L (1 week, <italic>P</italic> = 0.006), respectively. Meanwhile, 140.1 &#x000b1; 13.9&#x02009;<italic>&#x003bc;</italic>mol/L and 151.2 &#x000b1; 15.9&#x02009;<italic>&#x003bc;</italic>mol/L were observed for SCr in the control and BNP groups at 48&#x02009;h (<italic>P</italic> = 0.017), respectively, and 123.8 &#x000b1; 14.4&#x02009;<italic>&#x003bc;</italic>mol/L and 159.7 &#x000b1; 13.8&#x02009;<italic>&#x003bc;</italic>mol/L, respectively, at 1 week (<italic>P</italic> &#x0003c; 0.001). eGFR of 43.6 &#x000b1; 17.1&#x02009;mL/min and 40.2 &#x000b1; 18.7&#x02009;mL/min were observed in the control and BNP groups, respectively, at 48&#x02009;h (<italic>P</italic> = 0.046) and 50.4 &#x000b1; 14.9&#x02009;mL/min and 37.9 &#x000b1; 15.9&#x02009;mL/min at 1 week (<italic>P</italic> &#x0003c; 0.001). There were no significant differences between the two groups for the mean eGFR, cystatin C, and SCr values at 1 month.</p><p>Overall, eGFR gradually deteriorated until 1 week, followed by a mild improvement at 1 month in the control group, whereas the deterioration observed from 24&#x02009;h to 48&#x02009;h in the BNP group was completely restored at 1 week, and values remained at baseline until 1 month (<xref ref-type="fig" rid="fig3">Figure 3</xref>).</p></sec><sec id="sec3.4"><title>3.4. Adverse Effects</title><p>Besides the nine patients who suffered from complications before starting the trial, no patient presented adverse effects related to the use of rhBNP.</p></sec><sec id="sec3.5"><title>3.5. Subgroup Analysis</title><p>The predictors of CIN were explored. Univariate analyses showed that patients who developed CIN were more likely to be older (71.4 versus 62.1 years, <italic>P</italic> = 0.023), to have a history of diabetes (62.3% versus 35.8%, <italic>P</italic> = 0.011), to have hypertension (36.9% versus 22.4%, <italic>P</italic> = 0.031), to have received PCI (<italic>P</italic> = 0.014), to have received more CM (158 versus 78&#x02009;mL, <italic>P</italic> = 0.002), and to be non-BNP-treated (<italic>P</italic> &#x0003c; 0.001). After multivariate logistic regression analysis, only the CM volume (CM &#x0003e;100&#x02009;mL) and BNP administration were significant independent predictors of CIN (<xref ref-type="table" rid="tab3">Table 3</xref>).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>The results of this study showed that a more significant deterioration of eGFR, cystatin C, and SCr was observed in the control group compared to BNP-treated patients. Consequently, a lower incidence of CIN was observed in patients to whom rhBNP was administered. These findings strongly suggest that the prophylactic use of BNP before PCI or CAG may help prevent CIN.</p><p>CIN is commonly defined as a relative (&#x02265;25%) or absolute (&#x02265;0.5&#x02009;mg/dL) increase in SCr levels from baseline. Basically, SCr rises within the first 24&#x02013;48 hours after CM exposure, peaks at 3&#x02013;5 days, and returns near baseline values within 1&#x02013;3 weeks [<xref rid="B21" ref-type="bibr">21</xref>]. However, the SCr peak is postponed in patients with preexisting impaired renal function, and the increase may last for 7&#x02013;21 days [<xref rid="B2" ref-type="bibr">2</xref>]. In this study, SCr, eGFR, and cystatin C levels were deteriorated until 1 week after the procedure, before returning to baseline at 1 month in the control group. In contrast, a less pronounced deterioration of these kidney function markers was achieved in BNP-treated individuals, with a nadir observed at 48&#x02009;h and complete restoration to baseline levels by 1 week after the procedure. These findings indicate that BNP administration may have beneficial effects on renal function recovery after CM exposure. Among other functions described previously [<xref rid="B13" ref-type="bibr">13</xref>&#x02013;<xref rid="B15" ref-type="bibr">15</xref>], BNP was shown to positively affect the renal function [<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>], for example, increasing renal blood flow and glomerular filtration rate [<xref rid="B19" ref-type="bibr">19</xref>].</p><p>Apart from BNP administration, CM volume &#x0003e;100&#x02009;mL was found to be an independent predictor of CIN in this study. This finding is supported by previous reports demonstrating that large CM volumes are associated with an increased risk of CIN [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B23" ref-type="bibr">22</xref>, <xref rid="B24" ref-type="bibr">23</xref>]. Although no definitive threshold values have yet been established, CM volumes &#x02265;100&#x02013;200&#x02009;mL are associated with a higher incidence of CIN in high-risk patients [<xref rid="B25" ref-type="bibr">24</xref>]. It was found that, in patients undergoing PCI, each 100&#x02009;mL of CM is associated with a 12% increased risk of CI-AKI [<xref rid="B7" ref-type="bibr">7</xref>]. Taken together, CM volume should be limited as much as possible in high-risk patients.</p><p>A few limitations of the present study should be mentioned. First, the relatively small sample size prevents the generalization of our findings. In addition, this was a single center trial with the inherent selection bias. Finally, the study was not blinded. Therefore, multicenter, randomized, controlled trials with a larger sample size are required to further evaluate the beneficial effects of BNP on CIN.</p></sec><sec id="sec5"><title>5. Conclusions</title><p>Overall, this study showed that, in addition to hydration, exogenous administration of BNP before CM exposure is effective in decreasing the incidence of CIN in patients with CKD.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors express their gratitude to all the patients and the medical staff for their invaluable input.</p></ack><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackman</surname><given-names>D. J.</given-names></name><name><surname>Pinto</surname><given-names>R.</given-names></name><name><surname>Ross</surname><given-names>J. R.</given-names></name><etal/></person-group><article-title>Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention</article-title><source><italic>American Heart Journal</italic></source><year>2006</year><volume>151</volume><issue>1</issue><fpage>146</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.03.018</pub-id><pub-id pub-id-type="other">2-s2.0-29144493383</pub-id><pub-id pub-id-type="pmid">16368308</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katzberg</surname><given-names>R. W.</given-names></name></person-group><article-title>Urography into the 21st century: new contrast media, renal handling, imaging characteristics, and nephrotoxicity</article-title><source><italic>Radiology</italic></source><year>1997</year><volume>204</volume><issue>2</issue><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1148/radiology.204.2.9240511</pub-id><pub-id pub-id-type="other">2-s2.0-0030742750</pub-id><pub-id pub-id-type="pmid">9240511</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumlin</surname><given-names>J.</given-names></name><name><surname>Stacul</surname><given-names>F.</given-names></name><name><surname>Adam</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pathophysiology of contrast-induced nephropathy</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2006</year><volume>98</volume><issue>6</issue><fpage>14</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2006.01.020</pub-id><pub-id pub-id-type="other">2-s2.0-33747888493</pub-id><pub-id pub-id-type="pmid">16784912</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dangas</surname><given-names>G.</given-names></name><name><surname>Iakovou</surname><given-names>I.</given-names></name><name><surname>Nikolsky</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables</article-title><source><italic>The American Journal of Cardiology</italic></source><year>2005</year><volume>95</volume><issue>1</issue><fpage>13</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2004.08.056</pub-id><pub-id pub-id-type="other">2-s2.0-19944398728</pub-id><pub-id pub-id-type="pmid">15619387</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R.</given-names></name><name><surname>Aymong</surname><given-names>E. D.</given-names></name><name><surname>Nikolsky</surname><given-names>E.</given-names></name><etal/></person-group><article-title>A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2004</year><volume>44</volume><issue>7</issue><fpage>1393</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.06.068</pub-id><pub-id pub-id-type="other">2-s2.0-4644296839</pub-id><pub-id pub-id-type="pmid">15464318</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stacul</surname><given-names>F.</given-names></name><name><surname>van der Molen</surname><given-names>A. J.</given-names></name><name><surname>Reimer</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines</article-title><source><italic>European Radiology</italic></source><year>2011</year><volume>21</volume><issue>12</issue><fpage>2527</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.1007/s00330-011-2225-0</pub-id><pub-id pub-id-type="other">2-s2.0-83555173218</pub-id><pub-id pub-id-type="pmid">21866433</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rihal</surname><given-names>C. S.</given-names></name><name><surname>Textor</surname><given-names>S. C.</given-names></name><name><surname>Grill</surname><given-names>D. E.</given-names></name><etal/></person-group><article-title>Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention</article-title><source><italic>Circulation</italic></source><year>2002</year><volume>105</volume><issue>19</issue><fpage>2259</fpage><lpage>2264</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000016043.87291.33</pub-id><pub-id pub-id-type="other">2-s2.0-0037076345</pub-id><pub-id pub-id-type="pmid">12010907</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullough</surname><given-names>P. A.</given-names></name></person-group><article-title>Contrast-induced acute kidney injury</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2008</year><volume>51</volume><issue>15</issue><fpage>1419</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.12.035</pub-id><pub-id pub-id-type="other">2-s2.0-41549152928</pub-id><pub-id pub-id-type="pmid">18402894</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munagala</surname><given-names>V. K.</given-names></name><name><surname>Burnett</surname><given-names>J. C.</given-names><suffix>Jr.</suffix></name><name><surname>Redfield</surname><given-names>M. M.</given-names></name></person-group><article-title>The natriuretic peptides in cardiovascular medicine</article-title><source><italic>Current Problems in Cardiology</italic></source><year>2004</year><volume>29</volume><issue>12</issue><fpage>707</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1016/j.cpcardiol.2004.07.002</pub-id><pub-id pub-id-type="other">2-s2.0-8444220555</pub-id><pub-id pub-id-type="pmid">15550914</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boerrigter</surname><given-names>G.</given-names></name><name><surname>Burnett</surname><given-names>J. C.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Recent advances in natriuretic peptides in congestive heart failure</article-title><source><italic>Expert Opinion on Investigational Drugs</italic></source><year>2004</year><volume>13</volume><issue>6</issue><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1517/13543784.13.6.643</pub-id><pub-id pub-id-type="other">2-s2.0-3042847645</pub-id><pub-id pub-id-type="pmid">15174950</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valsson</surname><given-names>F.</given-names></name><name><surname>Ricksten</surname><given-names>S.-E.</given-names></name><name><surname>Hedner</surname><given-names>T.</given-names></name><name><surname>Lundin</surname><given-names>S.</given-names></name></person-group><article-title>Effects of atrial natriuretic peptide on acute renal impairment in patients with heart failure after cardiac surgery</article-title><source><italic>Intensive Care Medicine</italic></source><year>1996</year><volume>22</volume><issue>3</issue><fpage>230</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/BF01712242</pub-id><pub-id pub-id-type="other">2-s2.0-0029928914</pub-id><pub-id pub-id-type="pmid">8727437</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morikawa</surname><given-names>S.</given-names></name><name><surname>Sone</surname><given-names>T.</given-names></name><name><surname>Tsuboi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2009</year><volume>53</volume><issue>12</issue><fpage>1040</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2008.10.061</pub-id><pub-id pub-id-type="other">2-s2.0-61949457295</pub-id><pub-id pub-id-type="pmid">19298916</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocca</surname><given-names>H. P. B.-L.</given-names></name><name><surname>Kaye</surname><given-names>D. M.</given-names></name><name><surname>Woods</surname><given-names>R. L.</given-names></name><name><surname>Hastings</surname><given-names>J.</given-names></name><name><surname>Esler</surname><given-names>M. D.</given-names></name></person-group><article-title>Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2001</year><volume>37</volume><issue>5</issue><fpage>1221</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1016/s0735-1097(01)01172-x</pub-id><pub-id pub-id-type="other">2-s2.0-0035312862</pub-id><pub-id pub-id-type="pmid">11300426</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>S. J.</given-names></name><name><surname>Espiner</surname><given-names>E. A.</given-names></name><name><surname>Richards</surname><given-names>A. M.</given-names></name><name><surname>Yandle</surname><given-names>T. G.</given-names></name><name><surname>Frampton</surname><given-names>C.</given-names></name></person-group><article-title>Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man</article-title><source><italic>The Journal of Clinical Endocrinology and Metabolism</italic></source><year>1993</year><volume>76</volume><issue>1</issue><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="other">2-s2.0-0027514661</pub-id><pub-id pub-id-type="pmid">8380606</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohno</surname><given-names>M.</given-names></name><name><surname>Yokokawa</surname><given-names>K.</given-names></name><name><surname>Horio</surname><given-names>T.</given-names></name><name><surname>Yasunari</surname><given-names>K.</given-names></name><name><surname>Murakawa</surname><given-names>K.</given-names></name><name><surname>Takeda</surname><given-names>T.</given-names></name></person-group><article-title>Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta</article-title><source><italic>Circulation Research</italic></source><year>1992</year><volume>70</volume><issue>2</issue><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1161/01.res.70.2.241</pub-id><pub-id pub-id-type="other">2-s2.0-0026517440</pub-id><pub-id pub-id-type="pmid">1310444</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lingegowda</surname><given-names>V.</given-names></name><name><surname>Van</surname><given-names>Q. C.</given-names></name><name><surname>Shimada</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term outcome of patients treated with prophylactic nesiritide for the prevention of acute kidney injury following cardiovascular surgery</article-title><source><italic>Clinical Cardiology</italic></source><year>2010</year><volume>33</volume><issue>4</issue><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1002/clc.20750</pub-id><pub-id pub-id-type="other">2-s2.0-77950825061</pub-id><pub-id pub-id-type="pmid">20394042</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Winterstein</surname><given-names>A. G.</given-names></name><name><surname>Beaver</surname><given-names>T. M.</given-names></name></person-group><article-title>Projecting the effect of nesiritide on dialysis and hospital mortality in cardiac surgery patients</article-title><source><italic>Value in Health</italic></source><year>2010</year><volume>13</volume><issue>5</issue><fpage>643</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4733.2010.00710.x</pub-id><pub-id pub-id-type="other">2-s2.0-77955396238</pub-id><pub-id pub-id-type="pmid">20345547</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelesidis</surname><given-names>I.</given-names></name><name><surname>Mazurek</surname><given-names>J.</given-names></name><name><surname>Khullar</surname><given-names>P.</given-names></name><name><surname>Saeed</surname><given-names>W.</given-names></name><name><surname>Vittorio</surname><given-names>T.</given-names></name><name><surname>Zolty</surname><given-names>R.</given-names></name></person-group><article-title>The effect of nesiritide on renal function and other clinical parameters in patients with decompensated heart failure and preserved ejection fraction</article-title><source><italic>Congestive Heart Failure</italic></source><year>2012</year><volume>18</volume><issue>3</issue><fpage>158</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1111/j.1751-7133.2011.00272.x</pub-id><pub-id pub-id-type="other">2-s2.0-84861196716</pub-id><pub-id pub-id-type="pmid">22497779</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cea</surname><given-names>L. B.</given-names></name></person-group><article-title>Natriuretic peptide family: new aspects</article-title><source><italic>Current Medicinal Chemistry: Cardiovascular and Hematological Agents</italic></source><year>2005</year><volume>3</volume><issue>2</issue><fpage>87</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.2174/1568016053544309</pub-id><pub-id pub-id-type="other">2-s2.0-17144376356</pub-id><pub-id pub-id-type="pmid">15853696</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><collab>National Kidney Foundation</collab><article-title>K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification</article-title><source><italic>American Journal of Kidney Diseases</italic></source><year>2002</year><volume>39</volume><issue>2, supplement 1</issue><fpage>S1</fpage><lpage>S266</lpage><pub-id pub-id-type="pmid">11904577</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R.</given-names></name><name><surname>Nikolsky</surname><given-names>E.</given-names></name></person-group><article-title>Contrast-induced nephropathy: definition, epidemiology, and patients at risk</article-title><source><italic>Kidney International. Supplement</italic></source><year>2006</year><issue>100</issue><fpage>S11</fpage><lpage>S15</lpage><pub-id pub-id-type="other">2-s2.0-33746926391</pub-id><pub-id pub-id-type="pmid">16612394</pub-id></element-citation></ref><ref id="B23"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>J. R.</given-names></name><name><surname>Robb</surname><given-names>J. F.</given-names></name><name><surname>Block</surname><given-names>C. A.</given-names></name><etal/></person-group><article-title>Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?</article-title><source><italic>Circulation: Cardiovascular Interventions</italic></source><year>2010</year><volume>3</volume><issue>4</issue><fpage>346</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.109.910638</pub-id><pub-id pub-id-type="other">2-s2.0-77956262201</pub-id><pub-id pub-id-type="pmid">20587788</pub-id></element-citation></ref><ref id="B24"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marenzi</surname><given-names>G.</given-names></name><name><surname>Assanelli</surname><given-names>E.</given-names></name><name><surname>Campodonico</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality</article-title><source><italic>Annals of Internal Medicine</italic></source><year>2009</year><volume>150</volume><issue>3</issue><fpage>170</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-150-3-200902030-00006</pub-id><pub-id pub-id-type="other">2-s2.0-59949101995</pub-id><pub-id pub-id-type="pmid">19189906</pub-id></element-citation></ref><ref id="B25"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeder</surname><given-names>M.</given-names></name><name><surname>Klein</surname><given-names>M.</given-names></name><name><surname>Fehr</surname><given-names>T.</given-names></name><name><surname>Rickli</surname><given-names>H.</given-names></name></person-group><article-title>Contrast nephropathy: review focusing on prevention</article-title><source><italic>Journal of the American College of Cardiology</italic></source><year>2004</year><volume>44</volume><issue>9</issue><fpage>1763</fpage><lpage>1771</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2004.06.075</pub-id><pub-id pub-id-type="other">2-s2.0-7044245840</pub-id><pub-id pub-id-type="pmid">15519005</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Patient flowchart. Hypotension: systolic pressure &#x0003c;90&#x02009;mmHg.</p></caption><graphic xlink:href="BMRI2016-5985327.001"/></fig><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Incidence of CIN in the BNP and control groups according to different definitions of CIN.</p></caption><graphic xlink:href="BMRI2016-5985327.002"/></fig><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Changes of eGFR in the two groups after contrast media exposure.</p></caption><graphic xlink:href="BMRI2016-5985327.003"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Control group (&#x02212;) (<italic>n</italic> = 103)</th><th align="center" rowspan="1" colspan="1">BNP group (+) (<italic>n</italic> = 106)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Sex (male), <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">63 (61.2%)</td><td align="center" rowspan="1" colspan="1">70 (66.0%)</td><td align="center" rowspan="1" colspan="1">0.464</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">69.8 &#x000b1; 6.7</td><td align="center" rowspan="1" colspan="1">67.6 &#x000b1; 7.2</td><td align="center" rowspan="1" colspan="1">0.512</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">25.4 &#x000b1; 4.2</td><td align="center" rowspan="1" colspan="1">24.9 &#x000b1; 5.0</td><td align="center" rowspan="1" colspan="1">0.419</td></tr><tr><td align="left" rowspan="1" colspan="1">SBP</td><td align="center" rowspan="1" colspan="1">133.4 &#x000b1; 14.6</td><td align="center" rowspan="1" colspan="1">138.8 &#x000b1; 13.9</td><td align="center" rowspan="1" colspan="1">0.187</td></tr><tr><td align="left" rowspan="1" colspan="1">Baseline serum creatinine (<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">120.5 &#x000b1; 14.7</td><td align="center" rowspan="1" colspan="1">117.2 &#x000b1; 13.1</td><td align="center" rowspan="1" colspan="1">0.206</td></tr><tr><td align="left" rowspan="1" colspan="1">Estimated glomerular filtration rate (mL/min)</td><td align="center" rowspan="1" colspan="1">50.9 &#x000b1; 9.3</td><td align="center" rowspan="1" colspan="1">52.3 &#x000b1; 11.2</td><td align="center" rowspan="1" colspan="1">0.324</td></tr><tr><td align="left" rowspan="1" colspan="1">Cystatin C</td><td align="center" rowspan="1" colspan="1">1.17 &#x000b1; 0.36</td><td align="center" rowspan="1" colspan="1">1.14 &#x000b1; 0.22</td><td align="center" rowspan="1" colspan="1">0.275</td></tr><tr><td align="left" rowspan="1" colspan="1">History of diabetes mellitus, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">71 (68.9%)</td><td align="center" rowspan="1" colspan="1">76 (71.7%)</td><td align="center" rowspan="1" colspan="1">0.662</td></tr><tr><td align="left" rowspan="1" colspan="1">History of hypertension, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">59 (57.3%)</td><td align="center" rowspan="1" colspan="1">62 (58.5%)</td><td align="center" rowspan="1" colspan="1">0.860</td></tr><tr><td align="left" rowspan="1" colspan="1">Left ventricular ejection fraction, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">58.4 &#x000b1; 10.5</td><td align="center" rowspan="1" colspan="1">61.1 &#x000b1; 8.2</td><td align="center" rowspan="1" colspan="1">0.337</td></tr><tr><td align="left" rowspan="1" colspan="1">Isosorbide dinitrate, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">77 (74.8%)</td><td align="center" rowspan="1" colspan="1">75 (70.8%)</td><td align="center" rowspan="1" colspan="1">0.516</td></tr><tr><td align="left" rowspan="1" colspan="1">Low molecular heparin, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">98 (95.1%)</td><td align="center" rowspan="1" colspan="1">100 (94.3%)</td><td align="center" rowspan="1" colspan="1">0.794</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">102 (99%)</td><td align="center" rowspan="1" colspan="1">103 (97%)</td><td align="center" rowspan="1" colspan="1">0.622</td></tr><tr><td align="left" rowspan="1" colspan="1">Contrast volume (mL)</td><td align="center" rowspan="1" colspan="1">96 &#x000b1; 14.5</td><td align="center" rowspan="1" colspan="1">102 &#x000b1; 17.2</td><td align="center" rowspan="1" colspan="1">0.318</td></tr><tr><td align="left" rowspan="1" colspan="1">Contrast volume &#x0003e;100&#x02009;mL, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">62 (60.2%)</td><td align="center" rowspan="1" colspan="1">65 (61.3%)</td><td align="center" rowspan="1" colspan="1">0.757</td></tr><tr><td align="left" rowspan="1" colspan="1">Single-vessel disease, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">35 (34%)</td><td align="center" rowspan="1" colspan="1">37 (34.9%)</td><td align="center" rowspan="1" colspan="1">0.888</td></tr><tr><td align="left" rowspan="1" colspan="1">Double-vessel disease, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">42 (40.8%)</td><td align="center" rowspan="1" colspan="1">46 (43.4%)</td><td align="center" rowspan="1" colspan="1">0.701</td></tr><tr><td align="left" rowspan="1" colspan="1">Three-vessel disease, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">26 (25.2%)</td><td align="center" rowspan="1" colspan="1">23 (21.7%)</td><td align="center" rowspan="1" colspan="1">0.545</td></tr><tr><td align="left" rowspan="1" colspan="1">Coronary angiography, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">36 (35%)</td><td align="center" rowspan="1" colspan="1">33 (31.1%)</td><td align="center" rowspan="1" colspan="1">0.557</td></tr><tr><td align="left" rowspan="1" colspan="1">PCI, <italic>n</italic> (%)</td><td align="center" rowspan="1" colspan="1">67 (65%)</td><td align="center" rowspan="1" colspan="1">73 (68.9%)</td><td align="center" rowspan="1" colspan="1">0.557</td></tr></tbody></table><table-wrap-foot><fn><p>Note: continuous variables are expressed as mean &#x000b1; standard deviation. Categorical variables are presented as percentage. SBP: systolic blood pressure.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Changes of renal function before and after the procedure between the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Cystatin C (mg/L)</th><th align="center" rowspan="1" colspan="1">SCr (<italic>&#x003bc;</italic>mol/L)</th><th align="center" rowspan="1" colspan="1">eGFR (mL/min)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BNP group (<italic>n</italic> = 106)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">1.14 &#x000b1; 0.22</td><td align="center" rowspan="1" colspan="1">117.2 &#x000b1; 13.1</td><td align="center" rowspan="1" colspan="1">52.3 &#x000b1; 11.2</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;After procedure</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;24&#x02009;h</td><td align="center" rowspan="1" colspan="1">1.44 &#x000b1; 0.31<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">133.2 &#x000b1; 14.1<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">46.3 &#x000b1; 15.4<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;48&#x02009;h</td><td align="center" rowspan="1" colspan="1">1.56 &#x000b1; 0.29<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">140.1 &#x000b1; 13.9<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">43.6 &#x000b1; 17.1<sup>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1 week</td><td align="center" rowspan="1" colspan="1">1.20 &#x000b1; 0.24</td><td align="center" rowspan="1" colspan="1">123.8 &#x000b1; 14.4</td><td align="center" rowspan="1" colspan="1">50.4 &#x000b1; 14.9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1 month</td><td align="center" rowspan="1" colspan="1">1.16 &#x000b1; 0.20</td><td align="center" rowspan="1" colspan="1">120.7 &#x000b1; 15.1</td><td align="center" rowspan="1" colspan="1">50.9 &#x000b1; 18.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Control group (<italic>n</italic> = 103)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Baseline</td><td align="center" rowspan="1" colspan="1">1.17 &#x000b1; 0.36</td><td align="center" rowspan="1" colspan="1">120.5 &#x000b1; 14.7</td><td align="center" rowspan="1" colspan="1">50.9 &#x000b1; 9.3</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;After procedure</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;24&#x02009;h</td><td align="center" rowspan="1" colspan="1">1.51 &#x000b1; 0.44<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">137.4 &#x000b1; 14.1<sup>#</sup>
</td><td align="center" rowspan="1" colspan="1">46.8 &#x000b1; 12.6</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;48&#x02009;h</td><td align="center" rowspan="1" colspan="1">1.75 &#x000b1; 0.94<sup><italic>&#x02217;</italic>#</sup>
</td><td align="center" rowspan="1" colspan="1">151.2 &#x000b1; 15.9<sup><italic>&#x02217;</italic>#</sup>
</td><td align="center" rowspan="1" colspan="1">40.2 &#x000b1; 18.7<sup><italic>&#x02217;</italic>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1 week</td><td align="center" rowspan="1" colspan="1">1.88 &#x000b1; 0.82<sup><italic>&#x02217;</italic>#</sup>
</td><td align="center" rowspan="1" colspan="1">159.7 &#x000b1; 13.8<sup><italic>&#x02217;</italic>#</sup>
</td><td align="center" rowspan="1" colspan="1">37.9 &#x000b1; 15.9<sup><italic>&#x02217;</italic>#</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;1 month</td><td align="center" rowspan="1" colspan="1">1.19 &#x000b1; 0.26</td><td align="center" rowspan="1" colspan="1">129.6 &#x000b1; 14.6</td><td align="center" rowspan="1" colspan="1">48.2 &#x000b1; 15.7</td></tr></tbody></table><table-wrap-foot><fn><p>SCr: serum creatinine; eGFR: estimated glomerular filtration rate.</p></fn><fn><p>&#x02009;
<sup><italic>&#x02217;</italic></sup>
<italic>P</italic> &#x0003c; 0.05 versus the BNP group (data were analyzed using the independent samples <italic>t</italic>-test). <sup>#</sup>
<italic>P</italic> &#x0003c; 0.05 versus baseline within the same group (data were analyzed using repeated measure ANOVA and the Bonferroni post hoc test).</p></fn></table-wrap-foot></table-wrap><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Univariate and multivariate analyses of CIN predictors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">Univariate odds ratio (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th><th align="center" rowspan="1" colspan="1">Multivariate odds ratio (95% CI)</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">3.08 (2.23, 4.29)</td><td align="center" rowspan="1" colspan="1">0.023<sup><italic>&#x02217;</italic></sup>
</td><td align="center" rowspan="1" colspan="1">0.86 (0.62, 0.98)</td><td align="center" rowspan="1" colspan="1">0.344</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">4.71 (4.04, 6.13)</td><td align="center" rowspan="1" colspan="1">0.011<sup><italic>&#x02217;</italic></sup>
</td><td align="center" rowspan="1" colspan="1">2.12 (1.08, 3.66)</td><td align="center" rowspan="1" colspan="1">0.083</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">2.96 (1.75, 5.17)</td><td align="center" rowspan="1" colspan="1">0.031<sup><italic>&#x02217;</italic></sup>
</td><td align="center" rowspan="1" colspan="1">1.13 (0.61, 2.07)</td><td align="center" rowspan="1" colspan="1">0.184</td></tr><tr><td align="left" rowspan="1" colspan="1">Contrast volume &#x0003e;100&#x02009;mL</td><td align="center" rowspan="1" colspan="1">5.32 (4.13, 6.65)</td><td align="center" rowspan="1" colspan="1">0.002<sup><italic>&#x02217;</italic></sup>
</td><td align="center" rowspan="1" colspan="1">4.36 (2.23, 5.47)</td><td align="center" rowspan="1" colspan="1">0.004<sup><italic>&#x02217;</italic></sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Type of procedure</td><td align="center" rowspan="1" colspan="1">3.48 (2.06, 4.12)</td><td align="center" rowspan="1" colspan="1">0.014<sup><italic>&#x02217;</italic></sup>
</td><td align="center" rowspan="1" colspan="1">1.04 (0.61, 4.14)</td><td align="center" rowspan="1" colspan="1">0.321</td></tr><tr><td align="left" rowspan="1" colspan="1">BNP administration</td><td align="center" rowspan="1" colspan="1">6.27 (4.46, 8.23)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001<sup><italic>&#x02217;</italic></sup>
</td><td align="center" rowspan="1" colspan="1">0.21 (0.09, 0.46)</td><td align="center" rowspan="1" colspan="1">0.006<sup><italic>&#x02217;</italic></sup>
</td></tr></tbody></table><table-wrap-foot><fn><p>&#x02009;
<sup><italic>&#x02217;</italic></sup>
<italic>P</italic> &#x0003c; 0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article>